Increase in genomic research activities
to improve understanding of the health and diseases and discover
diseases-relevant biomarkers have increased the popularity of biobanks in
recent years. Biobanking refers to the practice of creating wide-range
repositories for the collection, processing, and preservation of biological
samples such as blood, plasma, urine, tissues, cells, nucleic acids, and others
for research and development activities. Rising incidences of cancer,
cardiovascular disorders, respiratory diseases, Alzheimer’s, etc. have led to
the development of disease-oriented biobanks, population-based biobanks, tissue
banks, blood banks, etc., which are contributing to the growth of the global
biobanking market. Besides, growing investments for drug development by
government and private players to support regenerative medical research is
accelerating the growth of the global biobanking market. The COVID-19 pandemic
highlighted the importance of gathering and preservation of samples and related
data to develop effective vaccines and treatments. As clinical trials are
becoming more frequent, the demand for population-based and disease-oriented
biobanks is increasing exponentially.
The rapid integration of advanced technologies
such as next-generation high-throughput sequencing and big data, automation and
data analytics have changed the traditional biobanks into virtual biobanks. More
informatics toolsets are becoming available to ensure the quality of
biospecimens and data. ISBER Biospecimen Science Working Group has developed an
informatic tool, Standard PRE analytical Code (SPREC) that identifies and
records the main pre-analytical factors that might impact the integrity of
sampled clinical fluids and solid biospecimens during sample collection,
processing, or storage. The integrity of biospecimen is essential to the
provision of high-quality tissue samples for research, effective and efficient
interconnectivity. Other informatics tools enable standardization of
biospecimen management and tracking including freezer inventory technologies
and freezer mapping systems, pre-packaged commercialized endeavors for PC
software, etc. Some cloud-based platforms are offering advantages such as
real-time, sharable, and easy-to-access biospecimen data that could help in
improving efficiency of obtaining approvals.
Biobanks: New Frontier for Digital
Health Research
Biobanks have proven their essential
role in gathering deeper understanding about diseases and finding new
approaches to prevention and cures. The biobanking market is showing no signs
of slowing down, with both academic and industry-focused analysts relying on
them for their research activities. With enhanced focus on precision
medicine—treatment and research methodologies based on an individual’s
lifestyle, environment, behavior, genetics, the opportunities can expand exponentially.
Biobanks can help one gain a bigger understanding of the relationships among
ancestries, personality traits, risk factors, etc., which can help provide a
holistic picture. However, biobanks go beyond the collection and storage as it
is an approach based on the longitudinal lifecycle of research.
Digital health platforms provide
technological foundation for helping researchers utilize biobanks to make
personal health information easier to collect and share. These platforms boost
growth and diversification of biobanks’ cohort registries, increase relance,
and sharpen their competitive advantage. The digital health technologies can
range from real-time analytics to customizable reporting and personalized
digital marketing and communications to strategy building. Electronic consent
forms for sampling can help eliminate the paperwork and create more efficient
and transparent records. Leveraging the use of smartphones, tablets, laptops,
and other mobile devices, app-based research and virtual clinical studies are
making personal health information easily accessible. Automation can also be
helpful in improving traceability, retrieval, and delivery speed of samples
while reducing the probability of human errors. This way automated biobank
storage systems can reduce operational and delivery costs of biobanking.
Virtual Biobanks
Virtual biobanks are emerging as a
suitable option for researchers to enable broader access to resources. In
virtual banking, information regarding biological specimen is stored in an
electronic database, irrespective of the specimens’ physical location. These
biobanks offer the ability to collect specific and rare samples which the
commercial biobanks cannot provide. One of the best advantages of biobanks is
that they make it possible to collect biospecimens from a wide range of
locations along with genetic-based information and other kinds of background
data into a virtual repository. This way, scientists can have access to
high-quality samples and donors can be guaranteed that their samples would be
utilized in relevant research projects. Moreover, the biological samples are
stored in a decentralized manner, which makes it possible for investors to
locate biospecimen quickly using digital platforms rather than contacting
multiple biobanks.
Rising Prevalence of Chronic Diseases to
Accelerate Biobanking
There has a significant growth in the
mortality rate due to chronic disorders around the world, owing to factors such
as lifestyle changes, excessive smoking and alcohol consumption, poor diet,
etc. This has led to an increased focus of healthcare on research and
development initiatives to control the occurrence or reduce the symptoms of
chronic diseases such as diabetes, high blood pressure, hyperthyroidism, heart
diseases, cancer, etc. Population-based biobanks collect samples and data at
regular intervals to compare the individuals that remain healthy with those
that develop an illness, which eventually helps in determining the extent to
which specific diseases are caused by genetic or environmental factors. This
approach can be helpful in identifying mutations to predict disease onset and developing
preventative measures. The disease-based biobanking focus on discovering
biomarkers of a specific diseases such as diabetes via collecting samples such
as tissue biopsies, blood, and other fluids from sick patients. This way,
researchers can better predict disease progression, mortality, and response to
certain medications and treatments in reducing the symptoms. The disease-based
biobanks are beneficial to discover new targeted therapies and generate
complementary data for robust findings, which are key to the development of
personalized medicines and pushing the healthcare field forward.
Challenges
Biobanking managers find difficulty in recruiting
skilled staff due to lack of experience and insufficient funding for training
and development activities. Besides, limited awareness and novelty of the
concept of biobanking as well as resistance from stakeholders are presenting
challenges for the establishment and expansion of biobanks across the world.
Moreover, reluctance of patients to donate their biospecimens and data
represent another challenge for biobank managers. However, partnerships with
private companies represent a potential source of income for biobanks but the
commercialization issues and benefit sharing might endanger mistrust among
stakeholders, especially the donors.
According to TechSci Research report on “Biobanks Market – Global Industry Size,
Share, Trends, Competition, Opportunity and Forecast, 2017-2027 Segmented By
Type (Disease Oriented Biobanks, Population Based Biobanks, Tissue Biobanks,
Others), By Sample Type (Blood Products, Biological Fluids, Nucleic Acid, Cell
Lines, Others), By Application (Therapeutics, Drug Discovery, Clinical
Diagnostics, Clinical Research), By End User (Academic & Research
Institutes, Pharmaceutical & Biotechnology Companies, Hospitals &
Clinics, Others), By Region”, the global biobanks market was valued USD40.70 billion in
2021 and is anticipated to grow at a formidable CAGR of 8.22% during the
forecast period. The market growth can be attributed to increasing investments
in research & development activities for advanced therapies such as cancer
and personalized medicines.
Web: https://www.techsciresearch.com